Reuters logo
BRIEF-Soleno Therapeutics receives positive opinion from European orphan committee for DCCR in Prader-Willi Syndrome
October 12, 2017 / 12:22 PM / 10 days ago

BRIEF-Soleno Therapeutics receives positive opinion from European orphan committee for DCCR in Prader-Willi Syndrome

Oct 12 (Reuters) - Soleno Therapeutics Inc

* Soleno Therapeutics receives positive opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome

* Soleno Therapeutics Inc - ‍COMP issues an opinion on granting of orphan drug designation, after which opinion is submitted to EC for adoption​

* Soleno Therapeutics Inc - granted a 10-year period of marketing exclusivity in EU after product approval​

* Soleno Therapeutics Inc - ‍study is anticipated to take approximately 9-12 months to complete and is expected to be initiated at end of 2017​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below